Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-10-19 00:00:00 ET · period of report 2023-10-17 · accession 0001209191-23-053178 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-19 | 2023-10-17 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $373.25 | -5,651 | 40.6K | -12% | -$2.11M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-17 | S | D | 5,651 | $373.25 | 40,603 | D | — | — |